|CAS Registry Number|
The combination drug tegafur/gimeracil/oteracil (trade name Teysuno, and TS-1 in Japan) is used for the treatment of advanced gastric cancer. It is also being developed for the treatment of hepatocellular carcinoma.
Mechanism of action
Oteracil mainly stays in the gut because of its low permeability, where it reduces the production of 5-FU by blocking the enzyme orotate phosphoribosyltransferase. Lower 5-FU levels in the gut result in a lower gastrointestinal toxicity.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|